Skip to Main Content


Skip Nav Destination
Issue Cover
Current Issue
Volume 140,
Issue 5,
August 4 2022

Issue Highlights

Latest in Blood
Free Articles
Plenary Papers
ShengPeng Wang; Bianbian Wang; Yue Shi; Tanja Möller; Rebekka I. Stegmeyer; Boris Strilic; Ting Li; Zuyi Yuan; Changhe Wang; Nina Wettschureck; Dietmar Vestweber; Stefan Offermanns
DOI: 10.1182/blood.2021014614
First Edition
Zachary C Holmes; Helen Tang; Congxiao Liu; Amy T Bush; Benjamin C Neubert; Yiqun Jiao; Megan Covington; Diana M. Cardona; Michelle C Kirtley; Benny J Chen; Nelson J. Chao; Lawrence A David; Anthony D. Sung
DOI: 10.1182/blood.2021015178
Clinical Trials and Observations
Shivani Handa; Jeong-Ok Lee; Andriy Derkach; Richard M. Stone; Alan Saven; Jessica K. Altman; Michael Rhodes Grever; Kanti R Rai; Madhulika Shukla; Shreya Vemuri; Skye Montoya; Justin Taylor; Omar Abdel-Wahab; Martin S. Tallman; Jae H. Park
DOI: 10.1182/blood.2022016183


Featured Content

Immune thrombocytopenia and adenoviral SARS-COV2 vaccines, genomics, and a risk assessment model of anti-CD19 CAR T-cell treatment outcomes in lymphoma

In this week’s episode we’ll discuss the factors influencing the development of immune thrombocytopenia after administration of the ChAdOx1 nCov-19 vaccine, learn about the genomic features underlying anti-CD19 CAR T-cell treatment failure in lymphoma, and introduce a new predictive model for risk assessment before CAR T-cell therapy for large B-cell lymphoma.

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Niemann and colleagues used the Danish clinical registry to provide a longitudinal view of the outcomes of patients with chronic lymphocytic leukemia (CLL) who become infected with COVID-19. Overall, outcomes have improved during the era of the Omicron variants, with 30-day mortality across all patients with CLL declining from 23% to 2%. However, patients requiring hospital care continue to have 30-day mortality as high as 23%, suggesting that this population should be considered for close monitoring and preemptive antiviral therapy.

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration

Nicolai and colleagues studied vaccine-induced thrombotic thrombocytopenia (VITT) and immune thrombocytopenia (ITP) following adenovirus-based COVID-19 vaccine administration. They isolated and characterized antiplatelet antibodies from 27 patients with VITT and 26 patients with isolated thrombocytopenia following ChAdOx1 n-Cov-19 vaccination and modeled antibody formation in mice. Intravenous rather than intramuscular injection triggers platelet-adenovirus aggregates that are phagocytosed by splenic macrophages, leading to B-cell responses, suggesting that avoiding intravenous administration could obviate this complication.

How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge

Cataland and colleagues describe a clinical approach to the follow-up of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) following acute hospitalization. The authors provide valuable recommendations for frequency of laboratory testing, timing of intervention with further immunosuppression, and monitoring for the known complications of iTTP.

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

Two articles investigate tumor characteristics that predict the failure of CD19-directed chimeric antigen receptor (CAR) T cells in the treatment of large B-cell lymphoma. In the first article, Jain et al report on the results of whole-genome sequencing of 51 tumor samples; they confirm that pretreatment complex structural variants, APOBEC mutational signature, reactive oxygen species-related genomic changes, and recurrent 3p21.31 chromosomal deletion predict CAR T failure... 

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Shalabi et al report on a phase 1 trial of a bivalent chimeric antigen receptor (CAR) T-cell product targeting both CD19 and CD22, including some patients whose CAR T-cell therapy had failed. The complete response rate was 60% in all patients and 71% in those without prior CAR T-cell therapy. However, expansion and persistence of the CAR T cells are limited, and the investigators developed a new vector based on laboratory studies that may optimize the persistence of the bivalent vector in the future. Until then, proceeding to stem cell transplantation in responding patients is advised.

Close Modal

or Create an Account

Close Modal
Close Modal